Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2013

Andrews Miles C, Behren Andreas, Chionh Fiona, Mariadason John, Vella Laura J, Do Hongdo, Dobrovic Alexander, Tebbutt Niall, Cebon Jonathan

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to Imidazoles
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 2

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to ras Proteins

Source

Identifiers

PMID: 24190114
DOI: 10.1200/JCO.2013.50.4118

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.PMID 24190114Read ↗

B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.Semantic proximity Read ↗

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.Semantic proximity Read ↗

BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.Semantic proximity Read ↗

Targeting the PI3K signaling pathway in KRAS mutant colon cancer.Semantic proximity Read ↗

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.Semantic proximity Read ↗

Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations.Semantic proximity Read ↗

High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cellsSemantic proximity Read ↗

Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer.Semantic proximity Read ↗

A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040Semantic proximity Read ↗

BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms.Semantic proximity Read ↗

BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.Semantic proximity Read ↗

The response of cancers to BRAF inhibition underscores the importance of cancer systems biology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.